Villalobos ZMA, Salazar AN, Valverde ZA, Arroyo SG

Idioma: Español
Referencias bibliográficas: 22
Paginas: 11-18
Archivo PDF: 689.42 Kb.

RESUMEN

El shock séptico (SS) es muy prevalente en la actualidad, situándose entre las principales 10 causas de muerte a nivel mundial. Por su perfil farmacológico, se ha propuesto en diversas ocasiones que el uso de esteroides en SS puede asociar un efecto benéfico en la sobrevida de los pacientes. Numerosos estudios se han realizado con el fin de demostrar el papel de los mismos, considerando tanto la farmacodinamia y farmacocinética de los corticoesteroides (CS), así como sus efectos finales a nivel de mortalidad, reversibilidad del estado de shock, y posibles efectos adversos. El objetivo de este artículo es discutir basado en la evidencia actual, el papel de estos fármacos en dicha patología con el fin de definir los distintos escenarios en los que el paciente puede beneficiarse de los mismos.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Kumar P, Jordan M, Caesar J, Miller S. Improving the management of sepsis in a district general hospital by implementing the 'Sepsis Six' recommendations. BMJ Qual Improv Rep 2015;4.

2. Patel GP, Balk RA. Systemic steroids in severe sepsis and septic shock. Am J Respir Crit Care Med 2012;185:133-139.

3. Mesotten D, Vanhorebeek I, Van den Berghe G. The altered adrenal axis and treatment with glucocorticoids during critical illness. Nat Clin Pract Endocrinol Metab 2008;4:496-505.

4. Annane D. Corticosteroids for severe sepsis: an evidence-based guide for physicians. Ann Intensive Care 2011;1:7.

5. Yarema TC, Yost S. Low-dose corticosteroids to treat septic shock: a critical literature review. Crit Care Nurse 2011;31:16-26.

6. Weber-Carstens S, Deja M, Hokema F, et al. Critical Care 2005;9:P389.

7. Annane D. Effect of Treatment With Low Doses of Hydrocortisone and Fludrocortisone on Mortality in Patients With Septic Shock. Jama 2002;288:862.

8. Minneci PC, Deans KJ, Eichacker PQ, Natanson C. The effects of steroids during sepsis depend on dose and severity of illness: an updated meta-analysis. Clin Microbiol Infect 2009;15:308-18.

9. Batzofin BM, Sprung CL, Weiss YG. The use of steroids in the treatment of severe sepsis and septic shock. Best Pract Res Clin Endocrinol Metab 2011;25:735-43.

10. Annane D, Bellissant E, Bollaert PE, et al. Corticosteroids in the treatment of severe sepsis and septic shock in adults: a systematic review. JAMA 2009;301:2362-2375.

11. Wang C, Sun J, Zheng J, et al. Low-dose hydrocortisone therapy attenuates septic shock in adult patients but does not reduce 28-day mortality:a meta-analysis of randomized controlled trials. Anesth Analg 2014;118:346- 357.

12. Dellinger RP, Levy MM, Rhodes A, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med 2013;39:165-228.

13. Seymour CW, Rosengart MR. Septic Shock: Advances in Diagnosis and Treatment. JAMA 2015;314:708-717.

14. Povoa P, Salluh JI, Martinez ML, et al. Clinical impact of stress dose steroids in patients with septic shock: insights from the PROWESSShock trial. Crit Care 2015;19:193.

15. Ranieri VM, Thompson BT, Barie PS, et al. Drotrecogin alfa (activated) in adults with septic shock. N Engl J Med 2012;366:2055-64.

16. Briegel J, Forst H, Haller M, et al. Stress doses of hydrocortisone reverse hyperdynamic septic shock. Critical Care Medicine 1999;27:723-732.

17. Sprung CL, Annane D, Keh D, et al. Hydrocortisone therapy for patients with septic shock. N Engl J Med 2008;358:111-124.

18. Oppert M, Schindler R, Husung C, et al. Low-dose hydrocortisone improves shock reversal and reduces cytokine levels in early hyperdynamic septic shock. Critical Care Medicine 2005;33:2457-2464.

19. Bollaert PE, Charpentier C, Levy B, Debouverie M, Audibert G, Larcan A. Reversal of late septic shock with supraphysiologic doses of hydrocortisone. Crit Care Med 1998;26:645- 650.

20. Investigators CS, Annane D, Cariou A, et al. Corticosteroid treatment and intensive insulin therapy for septic shock in adults: a randomized controlled trial. JAMA 2010;303:341-348.

21. Hermsen ED, Zapapas MK, Maiefski M, Ruoo ME, Freifield AG, Kalil AC. Validation and comparison of clinical prediction rules for invasive candidiasis in ICU patients: a matched case-control study. Critical Care 2011;15:R198.

22. Colombo AL, Guimaraes T, Sukienik T, Pasqualotto AC, Andreotti R, Queiroz-Telles F, Nouer SA, Nucci M. Prognostic factors and historical trends in the epidemiology of candidemia in critically ill patients. Intensive Care Med 2014;40:1489-1498.